TLR4 and pulpitis: HMGB1 inhibitors alleviate pulpitis by blocking its interaction with receptors such as RAGE and TLR4, leading to reduced pro-inflammatory cytokine production in a dose-dependent manner, as demonstrated by systemic intraperitoneal administration in animal studies.